RxDoctor Payments Data

Stephanie Kertes, NP

Adult Health · Elkhart, INNPI 1326414160

Payments from drug & device makers

$571in general payments, 2019–2025

Across 24 payments — averaging $23.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$142
  • GSK$74
  • Sanofi-aventis U.S. LLC$62
  • Novartis$61
  • Novo Nordisk$42
  • AbbVie$31
  • plus $158 from 7 others

What the payments were for

  • Food & beverage$571100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$571 in reported general payments places this provider in the 55th percentile of 391 adult health providers in Indiana.

See all adult health providers in Indiana

Medicare billing

Part B allowed, 2024
$16,050
Medicare patients
75
Services billed
192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban65$36,480
RexultiBrexpiprazole15$19,810
MyrbetriqMirabegron20$7,709
SymbicortBudesonide/Formoterol Fumarate13$3,045
Olanzapine71$1,031
Sertraline Hcl56$839
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen22$811
Atorvastatin Calcium42$709
Albuterol Sulfate HfaAlbuterol Sulfate19$612
Gabapentin22$497
Levothyroxine Sodium50$428
Hydroxyzine Hcl26$426
Tamsulosin Hcl39$404
Escitalopram Oxalate59$400
ClopidogrelClopidogrel Bisulfate36$395

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$29$36,48065 claims
Otsuka America Pharmaceutical, Inc.Rexulti$142$19,81015 claims
AstraZenecaSymbicort$29$3,04513 claims
Lilly USA, LLCOlanzapine$21$1,03171 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 391 adult health providers in Indiana.

Other adult health in Elkhart

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →